BMS-265246
BMS-265246 is a selective small molecule inhibitor targeting cyclin-dependent kinases 1 and 2 (CDK1/2) . It has been utilized in biochemical and cellular assays to study cell cycle progression and has shown antitumor activity in preclinical in vivo cancer models.
Product Specifications
CAS Number
582315-72-8
Product Name Alternative
Cyclin dependent kinase, COVID-19, CHI3L1, CDK1/CyclinB, CDK4/CyclinD, CDK2/CyclinE, CDK, A2780, Calu-3 cells, BMS265246, BMS-265246, BMS 265246, Angiotensin-converting Enzyme (ACE), MCF7 cells, inhibit, Inhibitor, iTreg cell, ovarian cancer, Pyrazolopyridine
Field of Research
Cell Biology, Metabolism Research
Purity
98.33% (May vary between batches)
Solubility
Ethanol:< 1 mg/mL (insoluble or slightly soluble) ;10% DMSO+90% Corn Oil:1 mg/mL (2.9 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble) ; DMSO:13.33 mg/mL (38.6 mM)
Smiles
CCCCOc1c (cnc2[nH]ncc12) C (=O) c1c (F) cc (C) cc1F
Molecular Formula
C18H17F2N3O2
Molecular Weight
345.34
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
